DAIICHI SANKYO Singapore Pte. Ltd.

Founded as Sankyo Shoten through a joint investment by businessmen Matasaku Shiobara, Shotaro Nishimura and Genjiro Fukui.

Launched digestive enzyme Taka-Diastase® (in 1894, Dr. Jokichi Takamine discovered the enzyme from a fungus).

Launched Adrenalin®, an adrenal cortex hormone agent.

Established plant in Shinagawa, Japan.

Dr. Umetaro Suzuki, a future Sankyo scientific adviser, made the world's first discovery of vitamin B1 (Orizanin®) in rice bran and established a foundation for the theory of vitamins.

Changed company name from Sankyo Shoten to Sankyo Co., Ltd. and appointed Dr. Jokichi Takamine as first president.

Founded as Arsemin Shokai by Dr. Shozaemon Keimatsu and five others

Launched Arsemin®, an antisyphilitic agent

Launched Neo-Arsemin®, another antisyphilitic agent

Changed company name from Arsemin Shokai to Daiichi Pharmaceutical Co., Ltd. Appointed Seinosuke Shibata as first president

Began manufacturing Japan's first synthetic agricultural chemical, the fumigant insecticide KOKUZOL®.

Launched Bosmin®, a vasoconstriction / hemostasis and asthma medicine

Established plant in Takatsuki, Japan

Listed on Tokyo Stock Exchange.

Launched Therapol®, the first sulfa drug produced in Japan

Established plant in Funabori, Japan

Listed on Tokyo Stock Exchange

Launched LULU® cold medicine.

Manufactured Chloromycetin®, the first antibiotic produced in Japan.

Launched Iscotin®, a medicine for tuberculosis

Launched Sankyo Ichoyaku (now Daiichi Sankyo Ichoyaku).

Launched Vitamedin®, a vitamin B1, B6 and B12 compound.

Completed construction of head office building in Nihonbashi, Japan

Launched Transamin®, an antiplasmin medicine

Established plant in Hiratsuka, Japan.

Launched Patecs®, the first form-fitting pain relief patch

Beginning of the period 1970–2004, marking ongoing development.

Launched Karoyan®, a hair restoration agent

Launched Krestin®, an anticancer drug.

Launched Neuer®, a peptic ulcer agent

Launched Cefmetazon®, a cephamycin-type antibiotic.

Established plant in Akita, Japan

Launched Captoril®, the world's first renin-angiotensin-type hypertensive drug.

Signed out-licensing agreement for Tarivid®, a broad-spectrum antibacterial agent, with Johnson & Johnson of the United States and Hoechst of Germany

Launched Zantac®, a therapeutic agent for peptic ulcers.

Established Sankyo USA Corporation in New York City and Sankyo Europe GmbH in Dusseldorf, Germany.

Launched natural-type interferon-β formulation Feron®

Launched Tarivid® in Japan and then-West Germany

Launched Loxonin®, an analgesic and anti-inflammatory agent.

Established plant in Onahama, Japan.

Launched Omnipark®, a contrast media

Launched Senlock Pellet® (now Daiichi Sankyo Core Block®), a gastrointestinal agent

Launched Regain®, a mini-bottled vitamin tonic.

Globally launched Mevalotin®, a groundbreaking HMG-CoA reductase inhibitor (hyperlipidemic drug). Launched Banan®, an antibiotic agent.

Invested in Luitpold-Werk GmbH Group.

Established Korea Daiichi Pharmaceutical Co., Ltd.

Awarded the Ohkochi Memorial Grand Production Prize for Mevalotin®.

Launched Cravit®, a broad-spectrum oral antibacterial agent

Completed construction of head office building in Nihonbashi, Japan.

Launched Acecol®, an antihypertensive agent.

Launched Kuromaru Drink®, a digestive tonic

Established Sankyo Pharma Inc. in New Jersey, United States.

Became the first pharmaceutical company in Japan to receive ISO 14001 environmental certification for its Onahama and Odawara plants. Established Sankyo Pharma Research Institute in California, United States.

Established Daiichi Pharmaceutical (Beijing) Co., Ltd. in China

Launched Fastic®, a drug for lowering blood sugar, and Olmesartan (Benicar® in the US and Olmetec® in Germany), an antihypertensive agent.

Launched Calblock®, a long-acting calcium channel blocker.

Launched Cystina C®, an over-the-counter vitamin C product

Launched Olmesartan in Japan.